



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



4-Biphenylacetic Acid

Item No. 38116

CAS Registry No.: 5728-52-9
Formal Name: [1,1'-biphenyl]-4-acetic acid
Synonyms: *p*-Biphenylacetic Acid, CI-83544, Felbinac, LY61017, NSC 16284
MF: C₁₄H₁₂O₂
FW: 212.2
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

4-Biphenylacetic acid is supplied as a solid. A stock solution may be made by dissolving the 4-biphenylacetic acid in the solvent of choice, which should be purged with an inert gas. 4-Biphenylacetic acid is slightly soluble in methanol and acetonitrile.

Description

4-Biphenylacetic acid is a non-steroidal anti-inflammatory drug (NSAID) and an active metabolite of the prodrug fenbufen (Item No. 28851).¹ It inhibits prostaglandin E₂ (PGE₂; Item No. 14010) synthesis in a cell-free assay (IC₅₀ = 3.2 μM). *In vivo*, 4-biphenylacetic acid (2 mg/kg) suppresses UV-induced erythema in guinea pigs. 4-Biphenylacetic acid (16 mg/kg) reduces inflammation in a rat model of adjuvant-induced arthritis. It decreases phenylquinone-induced writhing in mice (ED₅₀ = 9.9 mg/kg).²

References

1. Kerwar, S.S. Pharmacologic properties of fenbufen. *Am. J. Med.* **75(4B)**, 62-69 (1983).
2. Brodgen, R.N., Heel, R.C., Speight, T.M., *et al.* Fenbufen: A review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. *Drugs* **21(1)**, 1-22 (1981).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM